{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:45:08Z","timestamp":1790685908307,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>HER2 amplification in cervical cancer has been associated with worse clinical prognosis and a potential favorable response to HER2 inhibitors. Immunohistochemistry for the HER2 receptor is a universally accepted surrogate test for HER2 amplification, but no standardized scoring system currently exists for cervical carcinomas. In this study, we investigated HER2 overexpression in cervical squamous cell carcinoma and correlated it with HER2 amplification using fluorescence <jats:italic toggle=\"yes\">in situ<\/jats:italic> hybridization (FISH) and molecular methods. Seventy-two cases of human papillomavirus-associated cervical cancer were retrospectively reviewed, and at least 2 representative tumor sections were stained for HER2. HER2 scoring was performed using the 2018 American Society of Clinical Oncology\/College of American Pathologist breast cancer criteria, and cases with equivocal (2+) to positive (3+) expression were analyzed for HER2 amplification using FISH and next-generation sequencing. The average patient age was 50\u00a0yrs (range: 27\u201385\u00a0yr), with most patients being African American (73.6%) and diagnosed at FIGO stage I (65.3%). Nineteen (26.4%) had equivocal HER2 expression and 4 (5.5%) showed positive expression. Three of the 4 cases with positive expression had enough tumors for FISH, and all 3 were amplified. Three cases with equivocal expression showed HER2 polysomy on FISH, and none showed HER2 amplification. Late clinical stage, high tumor grade, and regional lymph node metastasis were significantly correlated with HER2 overexpression and HER2 amplification. Next-generation sequencing of the 3 HER2-amplified tumors showed amplification of various genes, including CD274, JAK2, BIRC3, and ERBB2, and a PIK3CA missense mutation. In summary, HER2 immunohistochemistry is a reliable predictive marker of HER2 amplification in cervical cancer.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001068","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T13:00:37Z","timestamp":1730379637000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Molecular and Clinicopathologic Characterization of HER2-overexpressed Squamous Cell Carcinoma of the Cervix"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6087-2335","authenticated-orcid":false,"given":"Rachelle P.","family":"Mendoza","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhurya","family":"Ramineni","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Doytcheva","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer C.","family":"Gabutan","sequence":"additional","affiliation":[{"name":"Department of Pathology, State University of New York Downstate Health Sciences University, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raavi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pathology, State University of New York Downstate Health Sciences University, Brooklyn, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyuk","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center, Rochester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Vemuri","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Briese","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Brannon","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anum","family":"Shahid","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Petras","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhaz","family":"Ud Dean","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Segal","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo R.","family":"Lastra","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin 2020;70(4):313]","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"R4-20250613","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ijgc-2021-003014","article-title":"Human papillomavirus-independent cervical cancer","volume":"32","author":"Fernandes","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"R6-20250613","doi-asserted-by":"crossref","first-page":"100579","DOI":"10.1016\/j.esmoop.2022.100579","article-title":"Recurrent or primary metastatic cervical cancer: current and future treatments","volume":"7","author":"Gennigens","year":"2022","journal-title":"ESMO Open"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1200\/OP.21.00795","article-title":"Current management of locally advanced and metastatic cervical cancer in the United States","volume":"18","author":"Pang","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"R10-20250613","first-page":"959","article-title":"The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma","volume":"27","author":"Fuchs","year":"2007","journal-title":"Anticancer Res"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/jcp.45.7.594","article-title":"Prognostic value of c-erbB-2 expression in uterine cervical carcinoma","volume":"45","author":"Hale","year":"1992","journal-title":"J Clin Pathol"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s004320050248","article-title":"Prognostic significance of c-erbB-2 protein expression in carcinoma of the cervix treated with radiotherapy","volume":"125","author":"Nishioka","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"R13-20250613","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/ijgc-00009577-200311000-00017","article-title":"Prognostic significance of c-erbB-2\/HER2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy","volume":"13","author":"Niibe","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"R14-20250613","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/1097-0142(19940201)73:3<668::AID-CNCR2820730327>3.0.CO;2-D","article-title":"c-erbB-2 Oncoprotein expression is associated with poor prognosis in squamous cell carcinoma of the cervix","volume":"73","author":"Oka","year":"1994","journal-title":"Cancer"},{"key":"R15-20250613","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/COC.0b013e3181e84634","article-title":"Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy","volume":"34","author":"P\u00e9rez-Regadera","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"R16-20250613","doi-asserted-by":"crossref","first-page":"665595","DOI":"10.3389\/fonc.2021.665595","article-title":"Validation of potential protein markers predicting chemoradioresistance in early cervical cancer by immunohistochemistry","volume":"11","author":"Jeong","year":"2021","journal-title":"Front Oncol"},{"key":"R17-20250613","doi-asserted-by":"crossref","first-page":"36219","DOI":"10.18632\/oncotarget.5283","article-title":"HER2 as a novel therapeutic target for cervical cancer","volume":"6","author":"Oh","year":"2015","journal-title":"Oncotarget"},{"key":"R18-20250613","doi-asserted-by":"crossref","first-page":"e0257976","DOI":"10.1371\/journal.pone.0257976","article-title":"Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis","volume":"16","author":"Itkin","year":"2021","journal-title":"PLoS One"},{"key":"R19-20250613","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"R20-20250613","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","article-title":"HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP Companion Society Session at the 2020 USCAP annual meeting","volume":"40","author":"Buza","year":"2021","journal-title":"Int J Gynecol Pathol"},{"key":"R21-20250613","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","article-title":"Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays","volume":"19","author":"Kadri","year":"2017","journal-title":"J Mol Diagn"},{"key":"R22-20250613","doi-asserted-by":"crossref","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"R23-20250613","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/jnen\/nly130","article-title":"Integrating a large next-generation sequencing panel into the clinical diagnosis of gliomas provides a comprehensive platform for classification from FFPE tissue or smear preparations","volume":"78","author":"Parilla","year":"2019","journal-title":"J Neuropathol Exp Neurol"},{"key":"R24-20250613","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yexmp.2013.06.011","article-title":"Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence","volume":"95","author":"Conesa-Zamora","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"R25-20250613","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000011934","article-title":"Frequent amplification of C-erbB2 (HER-2\/Neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections","volume":"56","author":"Sharma","year":"1999","journal-title":"Oncology"},{"key":"R26-20250613","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1600-0463.2009.02531.x","article-title":"HER2\/neu (c-erbB-2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens","volume":"117","author":"Lesnikova","year":"2009","journal-title":"APMIS"},{"key":"R27-20250613","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2407-4-59","article-title":"HER2 expression in cervical cancer as a potential therapeutic target","volume":"4","author":"Chavez-Blanco","year":"2004","journal-title":"BMC Cancer"},{"key":"R28-20250613","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cjp2.184","article-title":"An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification","volume":"7","author":"Shi","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"R29-20250613","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ijc.10627","article-title":"Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection","volume":"101","author":"Zhang","year":"2002","journal-title":"Int J Cancer"},{"key":"R30-20250613","doi-asserted-by":"crossref","first-page":"151443","DOI":"10.1016\/j.anndiagpath.2019.151443","article-title":"Role and significance of HER-2\/neu as a biomarker in the premalignant and malignant lesions of uterine cervix","volume":"45","author":"Varshney","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"R31-20250613","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4103\/0377-4929.56127","article-title":"HER-2\/neu expression in lesions of uterine cervix: is it reliable and consistent?","volume":"52","author":"Gupta","year":"2009","journal-title":"Indian J Pathol Microbiol"},{"key":"R32-20250613","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1158\/1078-0432.CCR-23-1078","article-title":"Assessing the genomic landscape of cervical cancers: clinical opportunities and therapeutic targets","volume":"29","author":"Friedman","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R33-20250613","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12881","article-title":"Landscape of genomic alterations in cervical carcinomas","volume":"506","author":"Ojesina","year":"2014","journal-title":"Nature"},{"key":"R34-20250613","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ctrv.2014.02.008","article-title":"HER2 aberrations in cancer: implications for therapy","volume":"40","author":"Yan","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R35-20250613","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay","volume":"19","author":"Ross","year":"2017","journal-title":"J Mol Diagn"},{"key":"R36-20250613","doi-asserted-by":"crossref","first-page":"e28656","DOI":"10.1002\/jmv.28656","article-title":"Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K\/AKT pathway","volume":"95","author":"Wei","year":"2023","journal-title":"J Med Virol"},{"key":"R37-20250613","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"R38-20250613","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/genes13020287","article-title":"Characterization of the genomic landscape in cervical cancer by next generation sequencing","volume":"13","author":"Qiu","year":"2022","journal-title":"Genes (Basel)"},{"key":"R39-20250613","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"R40-20250613","doi-asserted-by":"crossref","first-page":"677","DOI":"10.21037\/atm-21-853","article-title":"A comprehensive pan-cancer analysis of CD274gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients","volume":"9","author":"Gao","year":"2021","journal-title":"Ann Transl Med"},{"key":"R41-20250613","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jmedgenet-2018-105745","article-title":"Comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer identifies potential targets for cervical cancer early warning","volume":"56","author":"Huang","year":"2019","journal-title":"J Med Genet"},{"key":"R42-20250613","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/gcc.22365","article-title":"Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival","volume":"55","author":"Budczies","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"R43-20250613","doi-asserted-by":"crossref","first-page":"591","DOI":"10.21873\/cgp.20344","article-title":"Prognostic significance of the BIRC2-BIRC3 gene signature in head and neck squamous cell carcinoma","volume":"19","author":"Lee","year":"2022","journal-title":"Cancer Genomics Proteomics"},{"key":"R44-20250613","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.18632\/oncotarget.27632","article-title":"Validated limited gene predictor for cervical cancer lymph node metastases","volume":"11","author":"Bloomstein","year":"2020","journal-title":"Oncotarget"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T15:02:54Z","timestamp":1749826974000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001068","relation":{},"ISSN":["0277-1691","1538-7151"],"issn-type":[{"value":"0277-1691","type":"print"},{"value":"1538-7151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}